Natera, Inc.
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Stephen Leonard Chapman
- Full Time Employees
- 6,140
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- 13011 McCallen Pass Building A Austin TX United States 78753
- IPO Date
- Jul 1, 2015
- CIK
- 0001604821
- Website
- natera.com
- Similar Companies
- Business
- Natera, Inc. (NTRA) is a global leader in cell-free DNA (cfDNA) testing, specializing in noninvasive molecular diagnostics for oncology, women's health, and organ health. Founded in 2004 and headquartered in Austin, Texas, the company operates CAP-accredited and CLIA-certified laboratories in Austin, Texas, and San Carlos, California, with a global presence including facilities in the Netherlands and partnerships extending services to numerous countries worldwide. Natera leverages proprietary technology combining novel molecular biology and bioinformatics to detect genetic material from blood samples, enabling early risk assessment, recurrence detection, and personalized treatment decisions for clinicians and patients. The company's core offerings span women's health tests including Panorama, a non-invasive prenatal test (NIPT) screening for fetal chromosomal abnormalities such as Down syndrome with positive predictive value reporting; Horizon, advanced carrier screening for hundreds of genetic conditions; Vistara, single-gene NIPT for 25 additional conditions; Anora, a miscarriage analysis test; Spectrum, preimplantation genetic testing for IVF embryos; and Empower for hereditary cancer risk. In oncology, Natera provides Signatera, a personalized circulating tumor DNA (ctDNA) test for molecular residual disease (MRD) monitoring, recurrence detection, and treatment response evaluation across cancers like colorectal, bladder, lymphoma, and multiple myeloma; Altera for tumor genomic profiling to identify somatic mutations and clinical trials; Latitude, a tissue-free MRD test; and Empower for germline mutations. Organ health solutions feature Prospera, a donor-derived cfDNA test for kidney transplant rejection assessment. Recent developments include the launch of Signatera Genome, a genome-designed MRD assay achieving Medicare coverage; Latitude Tissue-Free MRD; Fetal Focus single-gene NIPT with an expanded version forthcoming; and a Panorama vanishing twin workflow. Natera raised its 2025 revenue guidance to $2.18-$2.26 billion following strong Q3 2025 results with record revenues and oncology test volume growth of 46.1% year-over-year, alongside plans for seven new MolDX submissions potentially worth $250-$300 million in gross profit. Strategic partnerships with BGI Genomics Co., Ltd. and Foundation Medicine, Inc. enhance genetic testing capabilities and market expansion in precision medicine, while new data from trials like IMvigor011 and upcoming presentations at the 2025 American Society of Hematology meeting underscore ongoing clinical validation.
Company News
Signatera™ in Head and Neck Cancer: Three New Publications Demonstrate Strong Clinical Performance and Actionability
Aware Super Pty Ltd as trustee of Aware Super Buys 16,018 Shares of Natera, Inc. $NTRA
Medicare Expands Coverage for Signatera™ MRD Test in Hepatocellular Carcinoma
Benzinga's 'Stock Whisper' Index: Five Stocks Investors Secretly Monitor But Don't Talk About Yet
Natera, Shake Shack, eBay And More On CNBC's ‘Final Trades'
1,598 Shares of Natera, Inc. $NTRA Purchased by Bosman Wealth Management LLC
Natera (NTRA) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
Parnassus Mid Cap Growth Fund: Q3 2026 Performance Review
Alger Dynamic Opportunities Fund Q3 2026 Portfolio Update
NTRA Q3 Earnings on Deck: Will Signatera Volume Growth Drive Results?
Weatherbie Specialized Growth Fund Q3 2026 Portfolio Update
Signatera™ Genome with Phased and Structural Variants Highlighted in ESMO Presidential Symposium, Supporting the Critical Role of MRD-Guided Treatment in Bladder Cancer
Which Healthcare ETF Is the Better Buy: Invesco’s Broad RSPH or First Trust’s Biotech FBT?
Natera Shares Real-World Analyses and Data at ASN Kidney Week 2026, Highlighting the Critical Need for Genetic Testing with Renasight™
Stanley Druckenmiller Has Bet Big on This 1 Healthcare Stock. Here's Why I Disagree.
Here Are Friday’s Top Wall Street Analyst Research Calls: Deckers Outdoor, Globe Life, Guardant Health, Hess Midstream LP, Kimberly-Clark, Natera, NVR, SpaceX, Thermo Fisher Scientific, and More
Biotech Giants vs. Emerging Innovators: Which ETF Is the Better Buy?
Natera Partners With TransCode to Advance Colorectal Cancer Trial
2,138 Natera, Inc. $NTRA Shares Acquired by SteelPeak Wealth LLC
ESMO 2026 Presentations Deepen the Evidence Base for Natera's Oncology Portfolio and Leadership in Ultrasensitive MRD Technology